The Medicines and Healthcare products Regulatory Agency of the U.K. reports that it granted a conditional marketing authorization for the medicine obecabtagene autoleucel, or Aucatzyl, a chimeric antigen receptor T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. The new conditional marketing authorization was granted on April 25 to Autolus Therapeutics (AUTL), the MHRA noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics: Promising Clinical Results and Strategic Initiatives Support Buy Rating
- Autolus Therapeutics: Promising Developments in Lupus Nephritis Drive Buy Rating
- Autolus Therapeutics to Present R&D Update April 23
- Promising Outlook for Autolus Therapeutics: Operational Efficiency and Strategic Positioning Drive Buy Rating
- Autolus Therapeutics Announces Leadership Transition in Finance
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue